Top-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free RVMD Stock Alerts $32.23 +0.51 (+1.61%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$31.33▼$32.4850-Day Range$26.56▼$33.5552-Week Range$15.44▼$35.60Volume997,438 shsAverage Volume1.36 million shsMarket Capitalization$5.31 billionP/E RatioN/ADividend YieldN/APrice Target$38.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Revolution Medicines alerts: Email Address Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.2% Upside$38.80 Price TargetShort InterestBearish9.96% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment-0.04Based on 4 Articles This WeekInsider TradingSelling Shares$375,735 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.17) to ($3.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector429th out of 938 stocksBiological Products, Except Diagnostic Industry63rd out of 154 stocks 2.5 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.80, Revolution Medicines has a forecasted upside of 20.2% from its current price of $32.29.Amount of Analyst CoverageRevolution Medicines has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.96% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Revolution Medicines has recently decreased by 4.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 1.1 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Revolution Medicines this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $375,735.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.17) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -8.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -8.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesMarch 21, 2024 | insidertrades.comRevolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,252 SharesMarch 28, 2024 | globenewswire.comRevolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 25, 2024 | americanbankingnews.comFinancial Comparison: Semper Paratus Acquisition (NASDAQ:LGST) vs. Revolution Medicines (NASDAQ:RVMD)March 22, 2024 | investing.comRevolution Medicines executive sells over $67,000 in stockMarch 22, 2024 | investing.comRevolution Medicines general counsel sells $39,542 in stockMarch 16, 2024 | finance.yahoo.comRVMD Apr 2024 36.000 callMarch 16, 2024 | finance.yahoo.comRVMD Apr 2024 33.000 putMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 15, 2024 | ca.finance.yahoo.comRVMD Sep 2024 21.000 putMarch 15, 2024 | finance.yahoo.comRVMD Mar 2024 33.000 putMarch 15, 2024 | finance.yahoo.comRVMD Mar 2024 36.000 callMarch 14, 2024 | ca.finance.yahoo.comRVMD Apr 2024 21.000 putMarch 14, 2024 | ca.finance.yahoo.comRVMD Apr 2024 21.000 callMarch 14, 2024 | finance.yahoo.comRevolution Medicines Inc. (US76155X1000.SG)March 11, 2024 | markets.businessinsider.comBuy Rating on Revolution Medicines Amid Promising RMC-6236 Trials for Multiple Cancer TreatmentsMarch 8, 2024 | markets.businessinsider.comMorgan Stanley Maintains Equal-Weight Rating for Revolution Medicines: Here's What You Need To KnowMarch 7, 2024 | finance.yahoo.comRVMD Apr 2024 31.000 putFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Revolution Medicines: Advancing RAS Inhibitors and Strong Financial OutlookFebruary 28, 2024 | finance.yahoo.comRevolution Medicines Full Year 2023 Earnings: Misses ExpectationsFebruary 27, 2024 | finance.yahoo.comRevolution Medicines, Inc. (RVMD)February 27, 2024 | markets.businessinsider.comBuy Rating Affirmed on Revolution Medicines: Anticipated Oncology Breakthroughs in H2 2024February 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Revolution Medicines (RVMD)February 27, 2024 | finance.yahoo.comQ4 2023 Revolution Medicines Inc Earnings CallFebruary 27, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Revolution Medicines (RVMD)February 26, 2024 | globenewswire.comRevolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressFebruary 23, 2024 | msn.comMediWheel's Seamless Digital Platform Redefines Outpatient CareSee More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees378Year FoundedN/APrice Target and Rating Average Stock Price Target$38.80 High Stock Price Target$47.00 Low Stock Price Target$28.00 Potential Upside/Downside+21.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-436,370,000.00 Net Margins-1,003.36% Pretax Margin-3,798.71% Return on Equity-38.39% Return on Assets-33.61% Debt Debt-to-Equity RatioN/A Current Ratio13.06 Quick Ratio13.06 Sales & Book Value Annual Sales$11.58 million Price / Sales454.25 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book2.88Miscellaneous Outstanding Shares164,690,000Free Float150,691,000Market Cap$5.26 billion OptionableOptionable Beta1.53 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Comp: $1.05MMr. Jack Anders (Age 47)Chief Financial Officer Comp: $544.8kMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Comp: $775.6kDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Comp: $779kMs. Xiaolin Wang (Age 53)Executive Vice President of Clinical Development Comp: $604.1kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsKrystal BiotechNASDAQ:KRYSHalozyme TherapeuticsNASDAQ:HALOImmunovantNASDAQ:IMVTCRISPR TherapeuticsNASDAQ:CRSPMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsStephen Michael KelseySold 2,123 sharesTotal: $67,044.34 ($31.58/share)Margaret A HornSold 2,914 sharesTotal: $92,024.12 ($31.58/share)Jack AndersSold 1,261 sharesTotal: $39,822.38 ($31.58/share)Jeff CisliniSold 1,252 sharesTotal: $39,538.16 ($31.58/share)Vanguard Group Inc.Bought 4,990,800 shares on 3/11/2024Ownership: 8.886%View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price target for 2024? 10 analysts have issued 12 month target prices for Revolution Medicines' stock. Their RVMD share price targets range from $28.00 to $47.00. On average, they predict the company's stock price to reach $38.80 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2024? Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD stock has increased by 12.6% and is now trading at $32.29. View the best growth stocks for 2024 here. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings data on Monday, February, 26th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by $0.29. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $1.20 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.39%. The firm's quarterly revenue was down 95.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.63) earnings per share. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.04%), Vanguard Group Inc. (13.36%), Vanguard Group Inc. (8.89%), Nextech Invest Ltd. (5.75%), BVF Inc. IL (5.46%) and Bellevue Group AG (4.65%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder and Xiaolin Wang. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVMD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.